---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-009438"
form_type: "8-K"
ticker: "BIAF"
cik: "0001712762"
company_name: "bioAffinity Technologies, Inc."
filed_at: "2024-03-08T23:59:59+00:00"
generated_at: "2026-06-05T00:38:13.446686+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# BioAffinity closes $2.5M direct offering of 1.6M shares and 1.6M warrants at $1.5625/unit

## Summary
- Offering includes 1.6M shares (registered direct) and 1.6M common warrants (private placement) at combined $1.5625/share.
- Warrants exercisable at $1.64 per share, subject to shareholder approval, expiring five years after approval date.
- Gross proceeds ~$2.5M; net proceeds for working capital and general corporate purposes.
- IPO warrant exercise price reduced to $3.0625 upon issuance of new shares and warrants.
- WallachBeth Capital acted as sole placement agent; closing occurred March 8, 2024.

## SEC filing metadata
- accession: 0001493152-24-009438
- form_type: 8-K
- ticker: BIAF
- cik: 0001712762
- company_name: bioAffinity Technologies, Inc.
- filed_at: 2024-03-08T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1712762/000149315224009438/0001493152-24-009438-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1712762/000149315224009438/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-009438
- JSON: https://secwatch.observer/filing/0001493152-24-009438.json
- Plain text: https://secwatch.observer/filing/0001493152-24-009438.txt

## Key facts
- Material Agreements
  bioAffinity Technologies, Inc. entered into Securities Purchase Agreement with four institutional investors valued at aggregate gross proceeds of approximately $2.5 million (effective 2024-03-06).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: four institutional investors
  - Value: aggregate gross proceeds of approximately $2.5 million
  - Effective: 2024-03-06
  source text: On March 6, 2024, bioAffinity Technologies, Inc. (the "Company") entered into a Securities Purchase Agreement (the "Purchase Agreement") with four institutional investors (the "Purchasers"), pursuant to which the Company will issue to the Purchasers, (i) in a registered direct offering, 1,600,000 shares of the Company’s common stock (the "Shares"), par value $0.007 per share ("Common Stock") and (ii) in a concurrent private placement, warrants to purchase an aggregate of 1,600,000 shares of Common Stock (the "Common Warrants") with an exercise price of $1.64.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1712762/000149315224009438/0001493152-24-009438-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.